Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients

Keyphrases

• Letrozole 100%
• Breast Cancer Patients 100%
• Aromatase Activity 100%
• Fadrozole 100%
• Metastatic Breast Cancer 40%
• Imidazole Derivatives 40%
• Cortisol 20%
• Estrogen 20%
• Estradiol 20%
• Aldosterone 20%
• Malignancy 20%
• Hormone-dependent 20%
• Vaginal Estrogen 20%
• Clinical Efficacy 20%
• Estrone 20%
• Aromatase Inhibitors 20%
• Hydrochloride 20%
• Postmenopausal Patients 20%
• Hormone Receptor-positive Breast Cancer 20%
• Non-steroidal 20%
• Orally Active 20%
• Efficacy Study 20%
• Second-line Treatment 20%
• Ablative Therapy 20%
• Estrone Sulfate 20%
• Second-line Therapy 20%

Medicine and Dentistry

• Breast Cancer 100%
• Letrozole 100%
• Aromatase 100%
• Fadrozole 100%
• Metastatic Breast Cancer 40%
• Imidazole Derivative 40%
• Low Drug Dose 20%
• Urinary System 20%
• Ablation Therapy 20%
• Aromatase Inhibitor 20%
• Cancer 20%
• Estrone 20%
• Hydrocortisone 20%
• Diethylstilbestrol 20%
• Aldosterone 20%
• Estrone Sulfate 20%
• Efficacy Study 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Aromatase 100%
• Fadrozole 100%
• Letrozole 100%
• Metastatic Breast Cancer 40%
• Imidazole Derivative 40%
• Hydrocortisone 20%
• Aromatase Inhibitor 20%
• Diethylstilbestrol 20%
• Aldosterone 20%
• Estrone 20%
• Efficacy Study 20%
• Estrone Sulfate 20%